PTC Therapeutics Inc (PTC Therapeutics) discovers, develops, and markets medicines for the treatment of rare disorders. Its marketed products include Evrysdi (risdiplam) for spinal muscular atrophy, Translarna (ataluren) and Emflaza (deflazacort) for the treatment of Duchenne muscular dystrophy. The company's pipeline candidates target the treatment of Huntington’s disease; children with inherited mitochondrial disease; leiomyosarcoma; acute myelogenous leukemia; and aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics works in collaboration with various biotechnology and pharmaceutical companies for advancing its pipeline candidates. The company operates through its subsidiaries in the US and Europe. PTC Therapeutics is headquartered in South Plainfield, New Jersey, the US.
Headquarters
United States of America
Address
100 Corporate Ct, South Plainfield, New Jersey, 07080-2400
Website
www.ptcbio.com
Telephone
1 908 2227000
No of Employees
1,252
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PTCT (NASD)
Revenue (2021)
$538.6M
41.4%
(2021 vs 2020)
EPS
XXX
Net Income (2021)
XXX
-19.6%
(2021 vs 2020)
Market Cap*
$2.6B
Net Profit Margin (2021)
XXX
15.5%
(2021 vs 2020)
* As of and is in US$
Explore premium data & analytics
Products and Services
| Products | Brands |
|---|---|
| Translarna (Ataluren): Duchenne Muscular Dystrophy | Evrysdi |
| Emflaza (Deflazacort): Duchenne Muscular Dystrophy | Translarna |
| Tegsedi (Inotersen): Polyneuropathy | Emflaza |
| XXX | XXX |
| XXX | XXX |
| XXX | XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Regulatory Approval | In May, the company announced that the U.S. Food and Drug Administration (FDA) approved a label extension for Evrysdi (risdiplam) to include infants under 2 months old with spinal muscular atrophy (SMA). |
| 2022 | Official Trials/Tests | In March, the company announced the initiation of the PIVOT-HD Phase 2 clinical trial evaluating PTC518 in people with Huntington's disease (HD). |
| 2022 | Official Trials/Tests | In March, the company initiated the PIVOT-HD Phase 2 clinical trial for evaluating PTC518 in patients with Huntington's disease. |
Competitor Comparison
| Key Parameters | PTC Therapeutics Inc | Astellas Pharma Inc | Biogen Inc | Daiichi Sankyo Co Ltd | Nippon Shinyaku Co Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | Japan | United States of America | Japan | Japan |
| City | South Plainfield | Chuo-Ku | Cambridge | Chuo-Ku | Kyoto-Shi |
| State/Province | New Jersey | Tokyo | Massachusetts | Tokyo | Kyoto |
| No. of Employees | 1,252 | 15,455 | 9,610 | 16,033 | 2,059 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Operating Margin
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael Schmertzler | Chairman | Executive Board | 2004 | 70 |
| Stuart W. Peltz, Ph.D. | Director; Chief Executive Officer | Executive Board | 1998 | 62 |
| Emily Hill | Chief Financial Officer | Senior Management | 2019 | 42 |
| Matthew B. Klein, M.D. | Chief Operating Officer | Senior Management | 2022 | 50 |
| Christine Utter | Head - People Services; Chief Accounting Officer; Senior Vice President | Senior Management | 2019 | 44 |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer